PURPOSE: The purpose of this study was to determine remission induction frequency when bortezomib was combined with daunorubicin and cytarabine in previously untreated older adults with acute myeloid leukemia (AML) and safety of bortezomib in combination with consolidation chemotherapy consisting of intermediate-dose cytarabine (Int-DAC). PATIENTS AND METHODS: Ninety-five adults (age 60 to 75 years; median, 67 years) with previously untreated AML (including therapy-related and previous myelodysplastic syndrome) received bortezomib 1.3 mg/m(2) intravenously (IV) on days 1, 4, 8, and 11 with daunorubicin 60 mg/m(2) on days 1 through 3 and cytarabine 100 mg/m(2) by continuous IV infusion on days 1 through 7. Patients who achieved complete remission (CR) received up to two courses of consolidation chemotherapy with cytarabine 2 gm/m(2) on days 1 through 5 with bortezomib. Three cohorts with escalating dose levels of bortezomib were tested (0.7, 1.0, and 1.3 mg/m(2)). Dose-limiting toxicities were assessed during the first cycle of consolidation. The relationship between cell surface expression of CD74 and clinical outcome was assessed. RESULTS: Frequency of CR was 65% (62 of 95), and 4% of patients (four of 95) achieved CR with incomplete platelet recovery (CRp). Eleven patients developed grade 3 sensory neuropathy. Bortezomib plus Int-DAC proved tolerable at the highest dose tested. Lower CD74 expression was associated with CR/CRp (P = .04) but not with disease-free or overall survival. CONCLUSION: The addition of bortezomib to standard 3 + 7 daunorubicin and cytarabine induction chemotherapy for AML resulted in an encouraging remission rate. The maximum tested dose of bortezomib administered in combination with Int-DAC for remission consolidation was 1.3 mg/m(2) and proved tolerable. Further testing of this regimen is planned.
PURPOSE: The purpose of this study was to determine remission induction frequency when bortezomib was combined with daunorubicin and cytarabine in previously untreated older adults with acute myeloid leukemia (AML) and safety of bortezomib in combination with consolidation chemotherapy consisting of intermediate-dose cytarabine (Int-DAC). PATIENTS AND METHODS: Ninety-five adults (age 60 to 75 years; median, 67 years) with previously untreated AML (including therapy-related and previous myelodysplastic syndrome) received bortezomib 1.3 mg/m(2) intravenously (IV) on days 1, 4, 8, and 11 with daunorubicin 60 mg/m(2) on days 1 through 3 and cytarabine 100 mg/m(2) by continuous IV infusion on days 1 through 7. Patients who achieved complete remission (CR) received up to two courses of consolidation chemotherapy with cytarabine 2 gm/m(2) on days 1 through 5 with bortezomib. Three cohorts with escalating dose levels of bortezomib were tested (0.7, 1.0, and 1.3 mg/m(2)). Dose-limiting toxicities were assessed during the first cycle of consolidation. The relationship between cell surface expression of CD74 and clinical outcome was assessed. RESULTS: Frequency of CR was 65% (62 of 95), and 4% of patients (four of 95) achieved CR with incomplete platelet recovery (CRp). Eleven patients developed grade 3 sensory neuropathy. Bortezomib plus Int-DAC proved tolerable at the highest dose tested. Lower CD74 expression was associated with CR/CRp (P = .04) but not with disease-free or overall survival. CONCLUSION: The addition of bortezomib to standard 3 + 7 daunorubicin and cytarabine induction chemotherapy for AML resulted in an encouraging remission rate. The maximum tested dose of bortezomib administered in combination with Int-DAC for remission consolidation was 1.3 mg/m(2) and proved tolerable. Further testing of this regimen is planned.
Authors: J Adams; V J Palombella; E A Sausville; J Johnson; A Destree; D D Lazarus; J Maas; C S Pien; S Prakash; P J Elliott Journal: Cancer Res Date: 1999-06-01 Impact factor: 12.701
Authors: Monica L Guzman; Carol F Swiderski; Dianna S Howard; Barry A Grimes; Randall M Rossi; Stephen J Szilvassy; Craig T Jordan Journal: Proc Natl Acad Sci U S A Date: 2002-11-25 Impact factor: 11.205
Authors: Martine E D Chamuleau; Yuri Souwer; S Marieke Van Ham; Adri Zevenbergen; Theresia M Westers; Johannes Berkhof; Chris J L M Meijer; Arjan A van de Loosdrecht; Gert J Ossenkoppele Journal: Cancer Res Date: 2004-08-15 Impact factor: 12.701
Authors: Eyal C Attar; Daniel J De Angelo; Jeffrey G Supko; Ferdinando D'Amato; David Zahrieh; Andres Sirulnik; Martha Wadleigh; Karen K Ballen; Steve McAfee; Kenneth B Miller; James Levine; Ilene Galinsky; Elizabeth G Trehu; David Schenkein; Donna Neuberg; Richard M Stone; Philip C Amrein Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531
Authors: William Blum; Sebastian Schwind; Somayeh S Tarighat; Susan Geyer; Ann-Kathrin Eisfeld; Susan Whitman; Alison Walker; Rebecca Klisovic; John C Byrd; Ramasamy Santhanam; Hongyan Wang; John P Curfman; Steven M Devine; Samson Jacob; Celia Garr; Cheryl Kefauver; Danilo Perrotti; Kenneth K Chan; Clara D Bloomfield; Michael A Caligiuri; Michael R Grever; Ramiro Garzon; Guido Marcucci Journal: Blood Date: 2012-05-07 Impact factor: 22.113
Authors: Bhavana Bhatnagar; Ann-Kathrin Eisfeld; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Dimitrios Papaioannou; Christopher J Walker; Shelley Orwick; James S Blachly; Jonathan E Kolitz; Bayard L Powell; Andrew J Carroll; Richard M Stone; John C Byrd; Clara D Bloomfield Journal: Leukemia Date: 2019-08-28 Impact factor: 11.528
Authors: Bhavana Bhatnagar; Ann-Kathrin Eisfeld; Deedra Nicolet; Krzysztof Mrózek; James S Blachly; Shelley Orwick; David M Lucas; Jessica Kohlschmidt; William Blum; Jonathan E Kolitz; Richard M Stone; Clara D Bloomfield; John C Byrd Journal: Br J Haematol Date: 2016-08-01 Impact factor: 6.998
Authors: Christopher J Walker; Jessica Kohlschmidt; Ann-Kathrin Eisfeld; Krzysztof Mrózek; Sandya Liyanarachchi; Chi Song; Deedra Nicolet; James S Blachly; Marius Bill; Dimitrios Papaioannou; Christopher C Oakes; Brian Giacopelli; Luke K Genutis; Sophia E Maharry; Shelley Orwick; Kellie J Archer; Bayard L Powell; Jonathan E Kolitz; Geoffrey L Uy; Eunice S Wang; Andrew J Carroll; Richard M Stone; John C Byrd; Albert de la Chapelle; Clara D Bloomfield Journal: Clin Cancer Res Date: 2019-08-02 Impact factor: 12.531
Authors: Alison R Walker; Rebecca Klisovic; Jeffrey S Johnston; Yao Jiang; Susan Geyer; Cheryl Kefauver; Philip Binkley; John C Byrd; Michael R Grever; Ramiro Garzon; Mitch A Phelps; Guido Marcucci; Kristie A Blum; William Blum Journal: Leuk Lymphoma Date: 2013-01-24